Fleetboston Financial Corp (FBF) Börsenkurse

Form S-8 - Securities to be offered to employees in employee benefit plans

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

AbbVie Completes Acquisition of Cerevel Therapeutics

AbbVie Completes Acquisition of Cerevel Therapeutics PR Newswire NORTH CHICAGO, Ill., Aug. 1, 2024 Cerevel's clinical-stage assets complement AbbVie's emerging neuroscience pipeline and leading...

Allergan Aesthetics Celebrates the Second Annual JUVÉDERM® Day

Allergan Aesthetics Celebrates the Second Annual JUVÉDERM® Day PR Newswire IRVINE, Calif., July 30, 2024 Join the seven million loyal Allē Members in celebrating the second annual JUVÉDERM® Day...

Alector Presents Baseline Characteristics for INVOKE-2 Phase 2 Clinical Trial of AL002 at the Alzheimer's Association International Conference® 2024 (AAIC®)

--INVOKE-2 is the first global Phase 2 trial evaluating the safety and efficacy of a TREM2 agonist, AL002, in slowing disease progression in individuals with early Alzheimer’s disease (AD...

AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis

AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis PR Newswire NORTH CHICAGO, Ill., July...

Form 8-K - Current report

AbbVie Reports Second-Quarter 2024 Financial Results

AbbVie Reports Second-Quarter 2024 Financial Results PR Newswire NORTH CHICAGO, Ill., July 25, 2024 Reports Second-Quarter Diluted EPS of $0.77 on a GAAP Basis, a Decrease of 32.5 Percent;...